142 related articles for article (PubMed ID: 38570214)
1. Prevention of potential delayed hemolytic transfusion reaction in two sickle cell patients using intravenous immunoglobulins and steroids before and after red blood cell exchange with antigen positive units and review literature.
Shold J; Dasgupta A; Ye Z
Transfus Apher Sci; 2024 Jun; 63(3):103920. PubMed ID: 38570214
[TBL] [Abstract][Full Text] [Related]
2. Transfusion of multiple units of Js(b+) red blood cells in the presence of anti-Jsb in a patient with sickle beta-thalassemia disease and a review of the literature.
Yuan S; Ewing NP; Bailey D; Salvador M; Wang S
Immunohematology; 2007; 23(2):75-80. PubMed ID: 18004938
[TBL] [Abstract][Full Text] [Related]
3. Anti-N and anti-Do
Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW
Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
[TBL] [Abstract][Full Text] [Related]
4. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review.
Win N; Sinha S; Lee E; Mills W
Transfus Med Rev; 2010 Jan; 24(1):64-7. PubMed ID: 19962576
[TBL] [Abstract][Full Text] [Related]
5. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction.
Cullis JO; Win N; Dudley JM; Kaye T
Vox Sang; 1995; 69(4):355-7. PubMed ID: 8751307
[TBL] [Abstract][Full Text] [Related]
6. Hyperhemolytic transfusion reaction in sickle cell disease.
Win N; Doughty H; Telfer P; Wild BJ; Pearson TC
Transfusion; 2001 Mar; 41(3):323-8. PubMed ID: 11274584
[TBL] [Abstract][Full Text] [Related]
7. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP
Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
[TBL] [Abstract][Full Text] [Related]
8. Prevention of hemolytic transfusion reactions with intravenous immunoglobulin prophylaxis in U- patients with anti-U.
Win N; Almusawy M; Fitzgerald L; Hannah G; Bullock T
Transfusion; 2019 Jun; 59(6):1916-1920. PubMed ID: 30861151
[TBL] [Abstract][Full Text] [Related]
9. Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.
Chonat S; Arthur CM; Zerra PE; Maier CL; Jajosky RP; Yee MEM; Miller MJ; Josephson CD; Roback JD; Fasano R; Stowell SR
Transfus Clin Biol; 2019 May; 26(2):130-134. PubMed ID: 30979566
[TBL] [Abstract][Full Text] [Related]
10. Transfusions of least-incompatible blood with intravenous immunoglobulin plus steroids cover in two patients with rare antibody.
Win N; Needs M; Thornton N; Webster R; Chang C
Transfusion; 2018 Jul; 58(7):1626-1630. PubMed ID: 29732576
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion.
Uhlmann EJ; Shenoy S; Goodnough LT
Transfusion; 2014 Feb; 54(2):384-8. PubMed ID: 23692505
[TBL] [Abstract][Full Text] [Related]
12. Delayed hemolytic transfusion reaction in children with sickle cell disease.
de Montalembert M; Dumont MD; Heilbronner C; Brousse V; Charrara O; Pellegrino B; Piguet C; Soussan V; Noizat-Pirenne F
Haematologica; 2011 Jun; 96(6):801-7. PubMed ID: 21330322
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
Aygun B; Padmanabhan S; Paley C; Chandrasekaran V
Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310
[TBL] [Abstract][Full Text] [Related]
14. Preventing antibody positive delayed hemolytic transfusion reactions in sickle cell disease: Lessons learned from a case.
Rankin A; Webb J; Nickel RS
Transfus Med; 2022 Oct; 32(5):433-436. PubMed ID: 35318744
[TBL] [Abstract][Full Text] [Related]
15. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review.
Win N; New H; Lee E; de la Fuente J
Transfusion; 2008 Jun; 48(6):1231-8. PubMed ID: 18373500
[TBL] [Abstract][Full Text] [Related]
16. Hyperhemolytic transfusion reaction attributable to anti-Fy3 in a patient with sickle cell disease.
Reyes MA; Illoh OC
Immunohematology; 2008; 24(2):45-51. PubMed ID: 19852130
[TBL] [Abstract][Full Text] [Related]
17. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
Balbuena-Merle R; Hendrickson JE
Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806
[TBL] [Abstract][Full Text] [Related]
18. Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease.
Fasano RM; Miller MJ; Chonat S; Stowell SR
Transfus Clin Biol; 2019 May; 26(2):94-98. PubMed ID: 30837199
[TBL] [Abstract][Full Text] [Related]
19. Alloimmunization in patients with sickle cell disease and underrecognition of accompanying delayed hemolytic transfusion reactions.
Coleman S; Westhoff CM; Friedman DF; Chou ST
Transfusion; 2019 Jul; 59(7):2282-2291. PubMed ID: 31021439
[TBL] [Abstract][Full Text] [Related]
20. Multiple hemolytic transfusion reactions misinterpreted as severe vaso-occlusive crisis in a patient with sickle cell disease.
Dean CL; Maier CL; Roback JD; Stowell SR
Transfusion; 2019 Feb; 59(2):448-453. PubMed ID: 30412270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
